A meta-analysis update: Percutaneous coronary interventions

American Journal of Managed Care

Volumn 14, Issue 8, 2008, Pages 521-528

  Cecil, William T ^a   Kasteridis, Panagiotis ^a   Barnes Jr , John W ^a   Mathis, Rick S ^a   Patric, Ken ^a   Martin, Steve ^a  

^a BlueCross BlueShield of Tennessee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; HEART DEATH; HEART INFARCTION; HUMAN; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZATION; RISK FACTOR; SYSTEMATIC REVIEW;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SURVIVAL ANALYSIS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME;

EID: 49549088145     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Grüntzig A. Transluminal dilation of coronary-artery stenosis. Lancet. 1978;1(8058):263.
2. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenoses: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301(2):61-68.
3. American Heart Association Web site. Percutaneous coronary interventions (previously called angioplasty, percutaneous transluminal coronary [PTCA], or balloon angioplasty). http://www.americanheart.org/presenter.jhtml? identifier=4454. Accessed December 13, 2007.
4. Gelijns A, Rosenberg N. The dynamics of technological change in medicine. Health Aff (Millwood). 1994;13(3):28-46.
5. Office of Technology Assessment, US Congress. Tools for Evaluating Health Technologies: Five Background Papers, BP-I-I-142. Washington, DC: US Government Printing Office; February 1995.
6. Office of Technology Assessment, US Congress. Medicare's Prospective Payment System: Strategies for Evaluating Cost, Quality, and Medical Technology. Washington, DC: US Government Printing Office; 1985.
7. Sawi D. Percutaneous transluminal coronary angioplasty. In: Strategies for Medical Technology Assessment. Washington, DC: Office of Technology Assessment, US Congress. September 1982:168-174.
8. Zweifel P. Chapter 8: Moral hazard and consumer incentives in health care. In: Culyer AJ, Newhouse JP, eds. Handbook of Health Economics. Vol 1A. Amsterdam, the Netherlands: Elsevier Science Publishers; 2000.
9. Kozak LJ, Hall MJ, Owings MF. National Hospital Discharge Survey: 2000 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2002;153:1-194.
10. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2001 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2004;156:1-198.
11. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2005;158:1-199.
12. Kozak LJ, Lees KA, DeFrances CJ. National Hospital Discharge Survey: 2003 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2006;160:1-206.
13. Kozak LJ, DeFrances CJ, Hall MJ. National Hospital Discharge Survey: 2004 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2006;162:1-209.
14. DeFrances CJ, Hall MJ. 2005 National Hospital Discharge Survey. Adv Data. 2007;385:1-19.
15. Feder BJ. Studies say newer stents for arteries show promise. New York Times. September 5, 2007. http://www.nytimes.com/2007/09/05/ business/05stent.html?_r=1&scp=1&sq= Studies%20say%20newer%20stents%20for%20arteries%20show%20promise&st= cse&oref=slogin〈http://www.nytimes.com/2007/09/05/business/05stent. html?_r=1&scp=1&sq= Studies%20say%20newer%20stents%20for%20arteries%20show%20promise&st= cse&oref=slogin〉. Accessed July 29, 2008.
16. Feder BJ. Market Place: First, a new artery stent study; now, questions about what it all means. New York Times. March 28, 2007. http://www.nytimes.com/2007/03/28/business/28place.html?scp=1&sq= Market+Place%3A+First%2C+a+new+artery+stent+study%3B+now%2C+questions+about+ what+it+all+means.&st=nyt 〈http://www.nytimes.com/2007/03/28/business/ 28place.html?scp=1&sq= Market+Place%3A+First%2C+a+new+artery+stent+study%3B+now%2C+questions+about+ what+it+all+means.&st=nyt〉. Accessed July 29, 2008.
17. Drug-coated stents are questioned. Wall Street Journal. September 5, 2007, D7.
18. Cheng, M. Doctors say drug-coated stents may not be so bad after all. Associated Press Newswires. September 2, 2007.
19. Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomized controlled trials. BMJ. 2000;321(7253):73-77.
20. Katritsis DG, Ioannidis PA. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation. 2005;111(22):2906-2912.
21. Boden WE, O'Rourke RA, Teo KK, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-1516.
22. Hochman JS, Lamas GA, Buller CE; Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355(23):2395-2407.
23. Pinto C. Doctors, insurers may differ on stents. Tennessean. April 2, 2007.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
25. Egger M, Davey Smith G, Altman D. Systematic Reviews in Health Care: Meta-analysis in Context. London, England: BMJ Books; 2001.
26. Wang M, Bushman B. Integrating Results Through Meta-analytic Review Using SAS Software. Cary, NC: SAS Institute Inc; 1999.
27. Whitehead A. Meta-analysis of Controlled Clinical Trials. New York, NY: John Wiley & Sons Inc; 2002.
28. Light RJ, Pillemer DB. Summing Up: The Science of Reviewing Research. Cambridge, MA: Harvard University Press; 1984.
29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
30. Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol. 2002;31(1):88-95.
31. Steme J, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304):101-105.
32. Tang J, Liu J. Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol. 2000;53(5):477-484.
33. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463.
34. Duval S, Tweedie R. A nonparametric "trim and fill" method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95(449):89-98.
35. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med. 2007;26(4):4544-4562.
36. Bech GJ, De Bruyne B, Pijls NH, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001;103(24):2928-2934.
37. Dakik HA, Kleiman NS, Farmer JA, et al. Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. Circulation. 1998;98(19):2017-2023.
38. Parisi AF, Folland ED, Hartigan PA. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med. 1992;326(1):10-16.
39. Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. J Am Coll Cardiol. 1997;29(7):1505-1511.
40. Hambrecht R, Walther C, Mobius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004;109(11):1371-1378.
41. Henderson RA, Pocock SJ, Clayton TC, et al; Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Sevenyear outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2003;42(7):1161-1170.
42. Hueb WA, Soares PR, Almeida De Oliveira S, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty, or bypass surgery for single proximal left anterior descending coronary artery stenosis. Circulation. 1999;100(Suppl 19):II107-II113.
43. Hueb WA, Soares PR, Gersh BJ, et al. The Medicine, Angioplasty, or Surgery Study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol. 2004;43(10):1743-1751.
44. Pitt B, Waters D, Brown WV, et al; Atorvastatin Versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341(2):70-76.
45. Sievers N, Hamm CW, Herzner A, Kuck KH. Medical therapy versus PTCA: a prospective randomized trial in patients with asymptomatic coronary single-vessel disease [abstract]. Circulation. 1993;88(suppl I):297.
46. Zeymer U, Uebis R, Vogt A, et al; ALKK-Study Group. Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausä rzte. Circulation. 2003;108(11):1324-1328.
47. Office of Technology Assessment, US Congress. Medical Technology and Costs of the Medicare Program. Washington, DC: US Government Printing Office; July 1984. Publication OTA-H-227.
48. Office of Technology Assessment, US Congress. Diagnosis Related Groups (DRGs) and the Medicare Program: Implications for Medical Technology: A Technical Memorandum. Washington, DC: US Government Printing Office; July 1983. Publication OTA-TM-H-17. This technical memorandum was performed as a part of OTA's assessment of Medical Technology and Costs of the Medicare Program.
49. McCullough PA, O'Neill WW, Graham M, et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy: results of the Medicine vs Angiography in Thrombolytic Exclusion (MATE) trial. J Am Coll Cardiol 1998;32(3):596-605.
50. TIM IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation. 1994;89(4):1545-1556.
51. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy [published correction appears in N Engl J Med. 1998;339(15);1091]. N Engl J Med. 1998;338(25):1785-1792. ■